203 related articles for article (PubMed ID: 23190892)
21. Genome-Wide Overexpression Screen Identifies Genes Able to Bypass p16-Mediated Senescence in Melanoma.
Lee WJ; Škalamera D; Dahmer-Heath M; Shakhbazov K; Ranall MV; Fox C; Lambie D; Stevenson AJ; Yaswen P; Gonda TJ; Gabrielli B
SLAS Discov; 2017 Mar; 22(3):298-308. PubMed ID: 27872202
[TBL] [Abstract][Full Text] [Related]
22. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
23. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma.
Funk JO; Schiller PI; Barrett MT; Wong DJ; Kind P; Sander CA
J Cutan Pathol; 1998 Jul; 25(6):291-6. PubMed ID: 9694617
[TBL] [Abstract][Full Text] [Related]
24. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.
de Keizer PL; Packer LM; Szypowska AA; Riedl-Polderman PE; van den Broek NJ; de Bruin A; Dansen TB; Marais R; Brenkman AB; Burgering BM
Cancer Res; 2010 Nov; 70(21):8526-36. PubMed ID: 20959475
[TBL] [Abstract][Full Text] [Related]
25. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
26. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF.
Sarkar-Agrawal P; Vergilis I; Sharpless NE; DePinho RA; Rünger TM
J Natl Cancer Inst; 2004 Dec; 96(23):1790-3. PubMed ID: 15572761
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
28. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
29. Contribution of p16(INK4a) to replicative senescence of human fibroblasts.
Brookes S; Rowe J; Gutierrez Del Arroyo A; Bond J; Peters G
Exp Cell Res; 2004 Aug; 298(2):549-59. PubMed ID: 15265701
[TBL] [Abstract][Full Text] [Related]
30. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
[TBL] [Abstract][Full Text] [Related]
31. Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts.
Huot TJ; Rowe J; Harland M; Drayton S; Brookes S; Gooptu C; Purkis P; Fried M; Bataille V; Hara E; Newton-Bishop J; Peters G
Mol Cell Biol; 2002 Dec; 22(23):8135-43. PubMed ID: 12417717
[TBL] [Abstract][Full Text] [Related]
32. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
Matsumura Y; Nishigori C; Yagi T; Imamura S; Takebe H
Arch Dermatol Res; 1998 Apr; 290(4):175-80. PubMed ID: 9617435
[TBL] [Abstract][Full Text] [Related]
33. Germline CDKN2A mutations in childhood melanoma.
Whiteman DC; Milligan A; Welch J; Green AC; Hayward NK
J Natl Cancer Inst; 1997 Oct; 89(19):1460. PubMed ID: 9326917
[No Abstract] [Full Text] [Related]
34. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
35. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
36. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
Wick ST; Dubay MM; Imanil I; Brizuela L
Oncogene; 1995 Nov; 11(10):2013-9. PubMed ID: 7478520
[TBL] [Abstract][Full Text] [Related]
37. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
Soto JL; Cabrera CM; Serrano S; López-Nevot MA
BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
[TBL] [Abstract][Full Text] [Related]
38. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
[TBL] [Abstract][Full Text] [Related]
39. E2FBP1 antagonizes the p16(INK4A)-Rb tumor suppressor machinery for growth suppression and cellular senescence by regulating promyelocytic leukemia protein stability.
Fukuyo Y; Takahashi A; Hara E; Horikoshi N; Pandita TK; Nakajima T
Int J Oral Sci; 2011 Oct; 3(4):200-8. PubMed ID: 22010578
[TBL] [Abstract][Full Text] [Related]
40. Familial cutaneous melanoma.
Hansson J
Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
